Updated trends in US brand-name and generic drug competition

Journal of Medical Economics, 2016 04: 1-9. e-pub ahead of print 2016/04/12

To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent challenges; and generic drug penetration.

View abstract


Grabowski H, Long G, Mortimer R, Boyo A.